
Journal of Medicinal Chemistry p. 425 - 432 (1993)
Update date:2022-09-26
Topics:
Burke Jr.
Lim
Marquez
Li
Bolen
Stefanova
Horak
A study was undertaken to prepare inhibitors of the lymphocyte protein- tyrosine kinase p56(lck). Using the known p56(lck) inhibitor 3,4-dihydroxy- α-cyanocinnamamide (4) as a lead compound, bicyclic analogues were designed as conformationally constrained
View MoreContact:86-511-85210668 0511-85210668, 85210818, 85210898
Address:Yihai Garden E-902,NO.99 Daxi RD., Zhenjiang Jiiangsu ,China
Shantou Baokang Pharmaceutical Co., Ltd.
Contact:+86-754-88873487
Address:5/F B Block Huangshan Bldg Huangshan Rd Shantou
Zhengzhou Minzhong Pharmaceutical Co.,ltd
Contact:0086-371-65797115
Address:15/F,Jiangshan Bldg, NO.126 Huanghe Road,Zhengzhou, China
Shanghai Xinda Pharmaceuticals Co., Ltd.
Contact:86-21-33692333-8008
Address:999 Linxian Road, Jinshan Industrial Park, Shanghai, China
Kaymossy BioChem Tech Co., Ltd
website:http://www.kaimosi.com
Contact:0571-87191913/0571-87199097
Address:Room 215, Building 3rd, No.288 Ningxia Road, Qingdao city, China
Doi:10.1021/ol202751s
(2011)Doi:10.1007/s00044-011-9857-0
(2012)Doi:10.1021/jm00080a028
(1992)Doi:10.1055/s-1991-26464
(1991)Doi:10.1021/jo00016a001
(1991)Doi:10.1021/ja01486a058
(1960)